Succesful quarter for Coherus Biosciences with Udenyca, a pegfilgrastim (Neulasta) biosimilar
Coherus BioSciences, Inc.announced that Udenyca preliminary unaudited net sales for the quarter that ended March 31, 2019 are expected to be in the range of $36.0 million to $38.0 million. Coherus will not disclose topline gross sales, discounts, or gross-to-net data until these data are reported in its Form 10-Q for the quarter ended March 31, 2019.
Coherus introduced Udenyca (pegfilgrastim-cbqv) in the U.S. marketplace on 3 January 2019 with a comprehensive launch across all segments including 340B hospitals, non-340B hospitals and clinics.
Comment:These results are about seven times higher than what analysts had predicted Coherus would earn from the first quarter of sales from its biosimilar, called Udenyca. Udenyca is the second biosimilar version of Neulasta to launch in the U.S., launching on 3 january 2019 with a list price 33% lower than the originator drug from Amgen. Another biosimilar, developed by Mylan, became available to patients in 2018.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.